Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Docetaxel
Related studies linked through entity extraction aliases.
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
- Status
- TERMINATED
- Phase
- PHASE2
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
- Status
- TERMINATED
- Phase
- PHASE1
Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
- Status
- UNKNOWN
- Phase
- PHASE2
Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients
- Status
- UNKNOWN
- Phase
- PHASE2
The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
- Status
- UNKNOWN
- Phase
- PHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate
- Status
- UNKNOWN
- Phase
- PHASE2
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3